BioAge Labs Inc.
BIOAHealthcare|Biotechnology|US
$5.34
-0.20 (-3.61%)
DCF Value
$8.93
Tangible Book / Share
$7.55
Cash / Share
$6.18
Clinical Trials (7)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT07656727 A Phase 2 Study to Evaluate the Pharmacodynamics, Safety and Tolerability of BGE-102 in Participants With Obesity and Cardiovascular Risk Factors | Obesity and Cardiovascular Risk | P2 | Active | 160 | RCT, Double-blind | Oral BGE-102, Oral Placebo Matching BGE-102 |
| NCT07812090 A Randomized, Phase 2 Study of Oral BGE-102 in Participants With Center-Involved Diabetic Macular Edema | Diabetic Macular Edema (DME) | P2 | Recruiting | 180 | RCT, Double-blind | Oral BGE-102, Oral Placebo Matching BGE-102, Anti-VEGF |
| NCT06515418 Efficacy and Safety of Oral Azelaprag Plus Once Weekly Tirzepatide Compared with Tirzepatide Alone in Participants with Obesity Aged 55 Years and Over | Obesity | P2 | Terminated | 204 | RCT, Double-blind | Oral Azelaprag (BGE-105), Oral Placebo for Azelaprag (BGE-105), Tirzepatide, Tirzepatide Placebo |
| NCT04815603 Study to Evaluate Efficacy and Safety of BGE-117 in the Treatment of Anemia of Aging | Anemia | P2 | Withdrawn | — | RCT, Double-blind | BGE-117 |
| NCT05152641 Study to Evaluate Efficacy and Safety of BGE-117 in Moderately to Severely Anemic Older Individuals After Major Hip Surgery | Acute Posthemorrhagic Anemia | P2 | Withdrawn | — | RCT, Double-blind | BGE-117, 4mg, BGE-117, 12mg |
| NCT04705597 Study to Evaluate the Safety, Tolerability, and Efficacy of BGE-175 in Hospitalized Adults With Coronavirus Disease 2019 (COVID-19) That Are Not in Respiratory Failure | Covid19 | P2 | Terminated | 194 | RCT, Double-blind | BGE-175 |
| NCT06141889 Pharmacokinetics Study of Azelaprag (BGE-105) in Older Adult Healthy Volunteers | Healthy Volunteer Study | P1 | Completed | 16 | RCT, Open-label | Azelaprag |